Get a full analysis report for any ticker →

SECTOR COVERAGE

Healthcare & Biotech Stock News

36 STORIES · UPDATED 4D AGO

Healthcare pairs durable cash flows with binary catalyst risk. We cover drug approvals, pipeline read-outs, and payer dynamics across pharma, med-tech, and providers — separating a real clinical inflection from a press-release pop.

By Basis Report Editorial DeskReviewed by Basis Report Methodology TeamMethodology
Top StoryHIMS

Hims & Hers Health Tumbles on Q2 Miss With 31.9% Float Short

Hims & Hers Health missed Q2 bottom-line consensus estimates as losses widened more than expected, sending shares lower despite a guidance raise for the next period.

THCBrief

Tenet Healthcare Lifted to $295 as BofA Holds Analyst Conviction

BofA Securities raised its Tenet Healthcare price target by $5 to $295 with no rating change, a modest confirmation of existing bullish conviction in …

PRAXAnalysis

Praxis Jumps on FDA Checks, Vormatrigine Misses Phase 3

Praxis Precision Medicines jumped 15.95% on August 6 after FDA mid-cycle reviews flagged no significant efficacy issues and clinical site inspections …

THCBrief

Tenet Healthcare Beats Peers in Q2, Still Trades at 12x Earnings

Tenet Healthcare topped its hospital chain peers in Q2 2026 earnings and trades at 12.3x forward P/E, a rare combination of operational rank and value…

THCAnalysis

Tenet Healthcare Surges on Blockbuster Q2 2026 Beat

Tenet Healthcare filed Q2 2026 results on July 23, posting EPS of $4.82 against estimates of approximately $4.165, extending a three-quarter streak of…

THCBrief

Tenet Healthcare Beats Q2 Earnings as Ambulatory Care Offsets Hospital Risks

Tenet Healthcare beat Q2 consensus EPS estimates and expanded margins, with ambulatory care growth carrying the company even as hospital policy pressu…

ARWRAnalysis

ARWR Jumps on Phase 3 Trial Win, Analysts Raise Targets

Arrowhead Pharmaceuticals surged after positive Phase 3 results that analysts called a "best-case scenario," with Piper Sandler and Chardan raising ta…

HIMSAnalysis

Hims & Hers Surges on Novo Nordisk Deal, Insiders Sell

Hims & Hers Health stock surged 14% to what news sources called its best single day ever on reports of a Novo Nordisk partnership, incinerating $546 m…

HIMSAnalysis

Hims & Hers Director Bets $1.2M as GLP-1 Battle Heats Up

Director David B Wells purchased $1.17 million in HIMS stock on May 26, days after a 13% earnings-driven drop that Reuters tied to the company's brand…

TEMAnalysis

Tempus AI CEO Sells $7.7M After Material Agreement

Tempus AI CEO Eric Lefkofsky and four other executives sold a combined $10.3 million in shares during May 2026, following a Material Definitive Agreem…

MANEBrief

Veradermics Hair-Loss Pill Posts Positive Results in 500-Man Trial

Veradermics' experimental oral hair-loss pill returned positive results in a 500-man trial, marking a key clinical milestone that could accelerate the…

ALHCAnalysis

ALHC Insiders Sell $24M as Stock Slides After Earnings

Alignment Healthcare beat earnings estimates in consecutive quarters and turned profitable, but the stock fell 19% as the market apparently priced in …

APLSAnalysis

Biogen Closes $5.6B Apellis Acquisition, APLS Delisted

Biogen completed its $5.6 billion acquisition of Apellis Pharmaceuticals on May 14, 2026, paying $41.00 per share in cash plus a contingent value righ…

HIMSBrief-9%

Hims & Hers Stock Falls 9% After $350 Million Leveraged Acquisition

Hims & Hers upsized a debt raise to $350M to fund the Eucalyptus acquisition alongside an AI initiative, triggering a ~9% share decline as investors q…

IBRXAnalysis

ImmunityBio Lands BCG Deal as Anktiva FDA Ruling Nears

ImmunityBio is acquiring U.S. rights to the Tokyo strain of BCG to target a decade-long bladder cancer shortage, while a pivotal FDA decision on its A…

IBRXBrief

ImmunityBio Grabs BCG Rights Ahead of Make-or-Break FDA Ruling

ImmunityBio is acquiring U.S. rights to Tokyo strain BCG while bracing for an imminent Anktiva FDA ruling, a dual catalyst that creates a binary risk …

OGNBrief

Organon Gets 24% Sun Pharma Buyout Bid at $13.25 Floor Price

Sun Pharma's all-cash offer for Organon at a 24% premium converts the stock from a fundamentals story into a merger arbitrage trade.

CPRXBrief

Catalyst Pharmaceuticals Pops on Angelini Takeover Talk, Target Lifted to $32

Catalyst Pharmaceuticals shares jumped on reports of acquisition interest from Italy's Angelini Pharma, with one analyst lifting the price target to $…

MOHBrief+14%

Molina Healthcare Stock Jumps 14% as Lower Medical Costs Overshadow $93M Charge

Molina Healthcare stock surged 14% after Q1 2026 earnings beat estimates on lower-than-expected medical costs, with the market ignoring a $93M impairm…

NKTRBrief

Nektar Therapeutics Raises $250 Million After Alopecia Drug Sends Stock Up 18%

Nektar Therapeutics is raising $250 million in a public stock offering timed to an 18.3% rally on positive alopecia trial data, a classic biotech move…

LEGNBrief+18%

Legend Biotech Surges 18% After Eli Lilly Strikes $7 Billion Cancer Therapy Deal

Eli Lilly struck a ~$7 billion deal tied to Legend Biotech's CARVYKTI cancer therapy, sending LEGN shares up as much as 18% for the stock's best sessi…

KLRABrief

Kailera Therapeutics Raises $625 Million in Biotech's Biggest IPO, Then Pops 63%

Kailera Therapeutics priced one of biotech's largest-ever IPOs at $625 million and saw shares surge roughly 63% on their first day, reflecting intense…

TVTXBrief+33%

Travere Therapeutics Surges 33% After FDA Approves the Only Drug for Rare Kidney Disease

Travere Therapeutics stock surged after FILSPARI became the first and only FDA-approved treatment for focal segmental glomerulosclerosis, a rare kidne…

TLXBrief

Telix Pharmaceuticals Jumps After FDA Accepts Brain Cancer Drug Filing

FDA accepted Telix Pharmaceuticals' NDA filing for its brain cancer imaging agent Pixclara, setting up a binary approval catalyst for the $804mn-reven…

IBRXBrief

ImmunityBio Got Promising Trial Data and an FDA Warning Letter in the Same Month

ImmunityBio confirmed its pivotal BCG-naive bladder cancer trial has adequate statistical power for a 2026 supplemental filing, but an FDA warning let…

ALHCBrief+16%

Alignment Healthcare Jumps 16% After Medicare Pays More Than Wall Street Expected

Alignment Healthcare surged 16% after CMS announced higher-than-expected 2026 Medicare Advantage reimbursement rates, boosting the outlook for a compa…

KODBrief

Kodiak Sciences Aces Second Phase 3 Trial for Zenkuda in Diabetic Retinopathy

Kodiak Sciences reported positive GLOW2 Phase 3 results showing Zenkuda achieved a 62.5% response rate vs 3.3% for sham in diabetic retinopathy, givin…

PRAXBrief

Praxis Precision Medicines Wins FDA Priority Review for Relutrigine NDA

Praxis Precision Medicines received FDA acceptance and Priority Review designation for its relutrigine NDA in rare pediatric epilepsy, compressing the…

CNTABrief

Eli Lilly to Buy Centessa Pharmaceuticals for Up to $7.8bn in Neuro Push

Eli Lilly announced a deal to acquire Centessa Pharmaceuticals for up to $7.8bn, paying $6.3bn upfront to secure the biotech's orexin receptor pipelin…

APLSBrief

Biogen to Acquire Apellis Pharmaceuticals for $5.6 Billion

Biogen agreed to acquire Apellis Pharmaceuticals for $5.6bn in cash plus potential milestone payments, sending APLS shares up more than 100% as the de…

GRDNBrief+9.1%

Jefferies Initiates GRDN at Buy With $44 Target, Stock Surges 9.1%

Jefferies initiated Guardian Pharmacy Services (GRDN) at Buy with a $44 price target Monday, sparking a 9.1% single-day rally and establishing institu…

KODAnalysis

Kodiak Sciences Needs Second Phase 3 Trial Despite "Superiority" Claims

Kodiak Sciences announced positive GLOW2 Phase 3 results for tarcocimab tedromer, but the need for a second confirmatory study suggests regulatory com…

CORTBrief

Corcept Therapeutics Gets FDA Approval for Ovarian Cancer Drug

FDA approved Corcept Therapeutics' Lifyorli combination therapy for platinum-resistant ovarian cancer, marking the company's expansion into oncology.

CORTAnalysis

Corcept Insider Drops $3.3M Just Before FDA Win Signals Hidden Value

A Corcept insider purchased $3.3 million in shares just before the company's FDA approval for Lifyorli, suggesting management confidence in broader pl…

AAPGAnalysis

Ascentage Pharma's Protein Degrader Pivot Signals Traditional Pipeline Crisis

Ascentage Pharma received China IND clearance for BTK protein degrader APG-3288, marking a strategic shift into unproven PROTAC technology. The pivot …

NNNNAnalysis

Anbio Biotechnology Management Disclosure Gap Signals Coverage Blind Spot

Anbio Biotechnology operates with minimal public disclosure, creating an information asymmetry that sophisticated investors can exploit. The company's…

Keep going

Sample Reports
See a full teardown end to end — DCF, earnings-quality score, and red flags on AAPL, NVDA, MSFT and more.
Browse the reports →
Free Tools
52 calculators — DCF, earnings-quality scorer, capital-allocation grader. No signup, no card.
Open the tools →
The Field Guide
50 plain-English chapters on valuation and earnings quality — how to read a filing the way we do.
Start reading →

Your move

Run this same teardown on a stock you actually own.

Drop in any ticker and get an institutional-grade report in about 60 seconds — the full DCF, an earnings-quality score, and the red flags buried deep in the filing. No signup, no card.

Run a free report →
  • DCF valuation with bull & bear cases
  • Earnings-quality score from 0–100
  • Red-flag scan across the 10-K
  • Peer multiples & a fair-value range